JP2021512614A5 - - Google Patents
Info
- Publication number
- JP2021512614A5 JP2021512614A5 JP2020542380A JP2020542380A JP2021512614A5 JP 2021512614 A5 JP2021512614 A5 JP 2021512614A5 JP 2020542380 A JP2020542380 A JP 2020542380A JP 2020542380 A JP2020542380 A JP 2020542380A JP 2021512614 A5 JP2021512614 A5 JP 2021512614A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- seq
- adhesion receptor
- target cell
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862628797P | 2018-02-09 | 2018-02-09 | |
| US62/628,797 | 2018-02-09 | ||
| US201862736965P | 2018-09-26 | 2018-09-26 | |
| US62/736,965 | 2018-09-26 | ||
| PCT/IB2019/000141 WO2019155286A2 (en) | 2018-02-09 | 2019-02-07 | Adhesion receptor constructs and uses thereof in natural killer cell immunotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021512614A JP2021512614A (ja) | 2021-05-20 |
| JP2021512614A5 true JP2021512614A5 (cg-RX-API-DMAC7.html) | 2022-02-09 |
Family
ID=67548047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542380A Pending JP2021512614A (ja) | 2018-02-09 | 2019-02-07 | ナチュラルキラー細胞免疫療法における接着受容体構築物及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210054409A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3749686A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2021512614A (cg-RX-API-DMAC7.html) |
| CN (1) | CN111712516A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019219452A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3089167A1 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202007183PA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019155286A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3805371A1 (en) | 2014-05-15 | 2021-04-14 | National University of Singapore | Modified natural killer cells and uses thereof |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| MX2019011570A (es) | 2017-03-27 | 2019-11-18 | Nat Univ Singapore | Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales. |
| CN117363636A (zh) | 2017-03-27 | 2024-01-09 | 新加坡国立大学 | 一种编码嵌合受体的多核苷酸 |
| JP7360174B2 (ja) | 2018-02-09 | 2023-10-12 | ナショナル ユニヴァーシティー オブ シンガポール | ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用 |
| US12441787B2 (en) | 2018-04-02 | 2025-10-14 | National University Of Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| WO2020044239A1 (en) | 2018-08-29 | 2020-03-05 | National University Of Singapore | A method to specifically stimulate survival and expansion of genetically-modified immune cells |
| CN113226340A (zh) | 2018-11-26 | 2021-08-06 | 恩卡尔塔公司 | 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途 |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| CN110396131B (zh) * | 2019-08-23 | 2020-07-10 | 北京鼎成肽源生物技术有限公司 | 一种ErbB2单链抗体、靶向人ErbB2的嵌合抗原受体、重组载体、重组细胞和应用 |
| CN114651003A (zh) | 2019-09-10 | 2022-06-21 | 黑曜石疗法公司 | 用于可调调节的ca2-il15融合蛋白 |
| CN115197326B (zh) * | 2022-06-27 | 2025-05-16 | 安徽医科大学第一附属医院 | 融合蛋白及其编码基因和重组载体以及它们的应用 |
| CN116554300B (zh) * | 2023-04-27 | 2023-10-24 | 湖北医药学院 | 一种能与艰难拟梭菌毒素TcdB相互作用的多肽及其应用 |
| CN120098148B (zh) * | 2025-05-09 | 2025-07-22 | 四川康德赛医疗科技有限公司 | 一种工程化巨噬细胞制备及抗纤维化的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| CA3040276A1 (en) * | 2009-12-02 | 2011-06-09 | Imaginab, Inc. | J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use |
| SG11201505858VA (en) * | 2013-01-28 | 2015-09-29 | St Jude Childrens Res Hospital | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
| EP3805371A1 (en) * | 2014-05-15 | 2021-04-14 | National University of Singapore | Modified natural killer cells and uses thereof |
| US10550197B2 (en) * | 2014-06-18 | 2020-02-04 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | CAR-expressing NK-92 cells as cell therapeutic agents |
| CN108136012B (zh) * | 2015-08-07 | 2022-10-04 | 伊麦吉纳博公司 | 靶向分子的抗原结合构建体 |
| ES2909973T3 (es) * | 2015-11-04 | 2022-05-10 | Hope City | Receptores quiméricos para el antígeno que se dirigen a HER2 |
| CN118652336A (zh) * | 2016-06-08 | 2024-09-17 | 普瑞赛格恩公司 | Cd33特异性嵌合抗原受体 |
| CN117363636A (zh) * | 2017-03-27 | 2024-01-09 | 新加坡国立大学 | 一种编码嵌合受体的多核苷酸 |
-
2019
- 2019-02-07 SG SG11202007183PA patent/SG11202007183PA/en unknown
- 2019-02-07 CA CA3089167A patent/CA3089167A1/en not_active Abandoned
- 2019-02-07 AU AU2019219452A patent/AU2019219452A1/en not_active Abandoned
- 2019-02-07 JP JP2020542380A patent/JP2021512614A/ja active Pending
- 2019-02-07 EP EP19750822.9A patent/EP3749686A4/en not_active Withdrawn
- 2019-02-07 CN CN201980011826.9A patent/CN111712516A/zh active Pending
- 2019-02-07 WO PCT/IB2019/000141 patent/WO2019155286A2/en not_active Ceased
- 2019-02-07 US US16/967,888 patent/US20210054409A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7499813B2 (ja) | 腫瘍壊死因子 (tnf) スーパーファミリー受容体結合分子およびその使用 | |
| KR102952460B1 (ko) | Cd3 항체 및 그의 약제학적 용도 | |
| CN112969476B (zh) | 多特异性蛋白分子 | |
| JP7029822B2 (ja) | 抗原特異的t細胞及びその使用 | |
| CN109963876B (zh) | 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备 | |
| JP2014518615A5 (cg-RX-API-DMAC7.html) | ||
| TWI867218B (zh) | 靶向her2的抗原結合建構體及用途 | |
| RS58448B1 (sr) | Antitela protiv antigena matičnih ćelija specifičan za prostatu i njihova upotreba | |
| TW201934582A (zh) | 抗pd-1/抗her2天然抗體結構樣異源二聚體形式雙特異抗體及其製備 | |
| CN112830969B (zh) | 一种特异性结合人Claudin18.2的单克隆抗体及包含其的药物和试剂盒 | |
| Spillner et al. | Recombinant IgE antibody engineering to target EGFR | |
| JP2023502108A5 (cg-RX-API-DMAC7.html) | ||
| Xing et al. | BiHC, a T-cell–engaging bispecific recombinant antibody, has potent cytotoxic activity against Her2 tumor cells | |
| Hayashi et al. | A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells | |
| RU2019104896A (ru) | Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и способы их использования | |
| US12534518B2 (en) | Fusion protein comprising anti-mesothelin antibody, anti-CD3 antibody or anti-EGFR antibody, bispecific or trispecific antibody comprising same, and uses thereof | |
| Zhao et al. | Recombinant human monoclonal igA antibody against CEA to recruit neutrophils to CEA-expressing cells | |
| CN119894930A (zh) | 一种双特异性抗体及其应用 | |
| JP2021520813A5 (cg-RX-API-DMAC7.html) | ||
| WO2024027828A1 (en) | Multi-specific antibodies targeting a dimerizable tumor antigen and an immunostimulatory antigen | |
| WO2024037627A1 (zh) | 一种双特异性抗体及其应用 | |
| CN117586408A (zh) | 一种结合tnfr2和b7h3的双特异性抗体 | |
| WO2026098577A1 (zh) | 抗ccr8抗体或其抗原结合片段及其应用 | |
| CN121064335A (zh) | 结合ror1和cd3的双特异性抗体及其用途 | |
| CN120192422A (zh) | 双特异性抗体及其应用 |